KING OF PRUSSIA, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day. Those wishing to participate may do so by dialing 1-412-317-6026 approximately ten minutes prior to start time. A listen-only webcast of the ca ...

KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) ("Vertex" or the "Company"), a global provider of indirect tax technology solutions, today announced the expansion of its Chief Strategy Office (CSO) with the addition of Christopher Hall and Kathya Capote Peimbert. Their extensive experience in e-invoicing, global tax compliance and ERP integration further reinforces Vertex's continued commitment to innovation and excellence, helping businesses navigate an increasingly compl ...

Core Viewpoint - Vertex Pharmaceuticals is positioned as a strong investment opportunity due to its robust growth prospects, ongoing drug portfolio diversification, and leadership in cystic fibrosis treatments, particularly with the success of its drug Trikafta [2][13]. Company Developments - Vertex has launched Casgevy, a gene-edited cell therapy for sickle cell disease, marking a significant advancement in its treatment offerings [3]. - The FDA approved Journavx, the first oral non-opioid painkiller in its class, which targets a large market of over 80 million U.S. patients with moderate-to-severe acute pain [4]. - The company aims to reduce its reliance on cystic fibrosis therapies, which currently account for over 93% of total revenue, by expanding into new therapeutic areas with Casgevy and Journavx [5]. Financial Performance - In 2024, Vertex reported total revenue of $11 billion, reflecting a 12% year-over-year increase, with growth accelerating in the fourth quarter [7]. - For 2025, the company projects revenue between $11.75 billion and $12.0 billion, indicating a 9% annual increase at the midpoint, driven by continued growth in cystic fibrosis and new product sales [8]. Market Position and Valuation - Vertex's sales growth trajectory contrasts with peers in the biotech industry, many of which face challenges such as patent cliffs and competition from generic drugs [9]. - The company's shares are trading at a forward price-to-earnings (P/E) ratio of 27, reflecting a valuation premium justified by its growth momentum compared to competitors like Gilead Sciences and Regeneron Pharmaceuticals [10][11]. Investment Outlook - Vertex's strong growth outlook, ongoing diversification of its drug portfolio, and solid fundamentals make it a compelling investment opportunity, with expectations for further upside in its stock price in 2025 [13].

Core Insights - Vertex Pharmaceuticals is experiencing positive momentum with its newly launched painkiller Journavx, which is gaining traction in both hospital and retail settings [2][3] - The drug is reportedly available on close to 90% of U.S. pharmacy shelves, indicating strong market penetration [2] - Vertex's 2025 revenue guidance is projected between $11.75 billion and $12 billion, primarily driven by cystic fibrosis therapies, with potential upside from Journavx and other therapies [3] Journavx Performance - Journavx has shown a strong start in the acute pain market, with coverage picking up faster than anticipated [3] - The drug is currently placed in Tier 3, but management emphasizes the overall value and positive anecdotal results from prescribing physicians and patients [3] Future Growth Potential - Two potential upside levers for Vertex's revenue in 2025 have been identified, with one already showing positive developments while the other is expected to take longer [3] - The company remains confident in its next-generation cystic fibrosis drug Alyftrek, despite challenges related to international intellectual property rights, particularly in Russia [4] Market Outlook - Vertex is expected to benefit from a rotation in the macro backdrop, supported by its high-quality profile and positive momentum in pain and gene therapy [4] - JPMorgan has reiterated its Overweight rating on Vertex, reflecting confidence in the company's growth prospects [5]

My previous investment thought on Vertex, Inc. (NASDAQ: VERX ) (published on 7th November) was a downgrade to a hold rating because I felt that the valuation was too high. I wouldn’t call thisI focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-term. Ultimately, I aim to identif ...

Global tax technology provider finds retail consumers want free, easy product returns -- or they’ll shop elsewhere to find themKING OF PRUSSIA, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, reveals that while free, easy product returns are paramount for consumer loyalty, they also create significant indirect tax complexities for retailers managing a surge of returns. Data from the post-holiday ‘Returnuar ...

Core Viewpoint - Goldman Sachs analyst Adam Hotchkiss has a positive outlook on Vertex, Inc. (VERX) ahead of its first Investor Day, maintaining a Buy rating with a price target of $48, citing the company's resilience against macroeconomic uncertainties due to the essential nature of tax software [1] Group 1: Revenue Growth and Market Dynamics - The analyst expects management to discuss the sustainability of mid-teens or higher revenue growth in the medium term [2] - Key points anticipated include the sustainability of demand and market dynamics within the enterprise tax software market [2] - The importance of e-invoicing and international expansion in driving future revenue growth is also expected to be highlighted [2] Group 2: Investment Roadmap and Margins - Clarity on the future investment roadmap and monetization of new product initiatives is anticipated [3] - The impact of these investments and scale-driven efficiencies on the company's medium-term margins is expected to be addressed [3] Group 3: Stock Performance - As of the last check, VERX shares have increased by 1.95%, reaching $34.25 [3]

Core Viewpoint - Vertex Pharmaceuticals has experienced a significant stock decline of 25.3% this year, contrasting with a 5.4% increase in the industry, despite recent product approvals that could drive future growth [1][2]. Group 1: Product Approvals and Sales Growth - Vertex gained approval for two new products: Journavx, a non-opioid pain medicine, and Alyftrek, a new cystic fibrosis (CF) treatment, which are expected to enhance sales [3][8]. - Vertex's CF product sales have consistently risen, with revenues increasing in the double-digit range for 10 consecutive years, driven by strong demand for Trikafta/Kaftrio, particularly in younger age groups [4][5]. - The launch of Alyftrek is anticipated to contribute to medium-term growth, while the ongoing demand for Trikafta/Kaftrio is expected to sustain sales in the near term [5][9]. Group 2: Diversification and Pipeline Development - The approval of Casgevy, a gene therapy for sickle cell disease and beta-thalassemia, diversifies Vertex's commercial opportunities, with an estimated patient population of around 60,000 in the U.S. and Europe [6][7]. - Vertex is advancing its pipeline with a focus on CF and other disease areas, including acute and neuropathic pain, with multiple candidates representing multibillion-dollar opportunities [13][14]. - The acquisition of povetacicept is expected to enhance Vertex's pipeline, targeting serious autoimmune diseases, with ongoing phase III and phase II studies [15]. Group 3: Financial Performance and Valuation - Vertex's stock is currently trading at a premium compared to the industry, with recent earnings estimates for 2025 and 2026 showing slight declines [16][19]. - Despite the premium valuation and declining estimates, Vertex is expected to achieve around 8% sales growth in 2025, driven by CF franchise growth and contributions from new products [25][26].

Company Overview - Vertex, Inc. is a leading global provider of indirect tax solutions, focusing on delivering trusted tax technology for global businesses to transact, comply, and grow with confidence [3] - The company offers tailored solutions for major lines of indirect tax, including sales and consumer use, value added, and payroll [3] - Vertex is headquartered in North America and has offices in South America and Europe, helping leading brands simplify the complexity of continuous compliance [3] Investor Day Announcement - Vertex, Inc. will host an Investor Day on March 19, 2025, in Philadelphia, PA, featuring presentations and a Q&A session with the executive leadership team [1] - The event will start at 8:30 a.m. ET and is expected to conclude around 12:00 p.m. ET, with in-person attendance being by invitation only and requiring advanced registration [2] - A live video broadcast of the event will be available on the company's Investor Relations website, with a replay accessible shortly after the event concludes [2]

Core Insights - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has experienced a modest stock price increase of 4% since mid-December, indicating a period of recovery after facing challenges [2]. Company Overview - Vertex Pharmaceuticals is based in Boston and is recognized as a significant player in the pharmaceutical industry [2]. - The company has been under the coverage of a biotech consultant with over 5 years of experience in the sector, who has produced detailed reports on more than 1,000 companies [2]. Investment Insights - The investment group Haggerston BioHealth offers resources for both novice and experienced biotech investors, including catalysts to monitor, buy and sell ratings, and forecasts for product sales across major pharmaceutical companies [2]. - The group also provides integrated financial statements, discounted cash flow analysis, and market-by-market analysis, which are essential for informed investment decisions [2].